EQT Life Sciences — 2026 Investments

1 investments dated 2026 · listed companies and verified rows first · show all

Xeltisxeltis.com in 𝕏Aug 2026

Xeltis develops implantable vascular devices that transform into living tissue using Restorex supramolecular polymer technology.

BiotechDeep TechHealthtechMedical Devices

Eliane Schutte(Chief Executive Officer)

Co-investorsKurma Partners VI Partners Ysios Capital Invest-NL

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.